SM-Youtube

Year	Number of Results
1993	1
1994	1
1996	1
1997	4
1998	2
1999	1
2000	1
2002	2
2003	2
2004	5
2005	1
2006	4
2007	2
2008	3
2009	1
2010	2
2011	2
2012	4
2013	9
2014	11
2015	20
2016	16
2017	19
2018	18
2019	14
2020	6
2021	2
2023	1
2024	0

1

Designer benzodiazepine rat pharmacokinetics: A comparison of alprazolam, flualprazolam and flubromazolam.

Canfield JR, Kisor DF, Sprague JE. Canfield JR, et al. Toxicol Appl Pharmacol. 2023 Apr 15;465:116459. doi: 10.1016/j.taap.2023.116459. Epub 2023 Mar 11. Toxicol Appl Pharmacol. 2023. PMID: 36907383 Free article.

2

The Evolving Landscape of Designer Drugs.

Kacinko SL, Papsun DM. Kacinko SL, et al. Methods Mol Biol. 2019;1872:129-135. doi: 10.1007/978-1-4939-8823-5_13. Methods Mol Biol. 2019. PMID: 30350286

3

Metabolism of designer drugs of abuse: an updated review.

Meyer MR, Maurer HH. Meyer MR, et al. Curr Drug Metab. 2010 Jun 1;11(5):468-82. doi: 10.2174/138920010791526042. Curr Drug Metab. 2010. PMID: 20540700 Review.

4

Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis.

Maurer HH, Kraemer T, Springer D, Staack RF. Maurer HH, et al. Ther Drug Monit. 2004 Apr;26(2):127-31. doi: 10.1097/00007691-200404000-00007. Ther Drug Monit. 2004. PMID: 15228152 Review.

5

Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.

Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, Ellis RJ, Richie CT, Harvey BK, Dannals RF, Pomper MG, Bonci A, Michaelides M. Gomez JL, et al. Science. 2017 Aug 4;357(6350):503-507. doi: 10.1126/science.aan2475. Science. 2017. PMID: 28774929 Free PMC article.

6

Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.

Kraemer T, Maurer HH. Kraemer T, et al. Ther Drug Monit. 2002 Apr;24(2):277-89. doi: 10.1097/00007691-200204000-00009. Ther Drug Monit. 2002. PMID: 11897973 Review.

7

Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.

Moosmann B, Bisel P, Auwärter V. Moosmann B, et al. Drug Test Anal. 2014 Jul-Aug;6(7-8):757-63. doi: 10.1002/dta.1628. Epub 2014 Mar 6. Drug Test Anal. 2014. PMID: 24604775

8

Designer drugs that are potent inhibitors of CYP2D6.

Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM. Pritzker D, et al. J Clin Psychopharmacol. 2002 Jun;22(3):330-2. doi: 10.1097/00004714-200206000-00015. J Clin Psychopharmacol. 2002. PMID: 12006905

9

Controversies in anaesthesia--designer drugs.

Henderson F, Kenny GN. Henderson F, et al. Ann Acad Med Singap. 1999 May;28(3):434-9. Ann Acad Med Singap. 1999. PMID: 10575531 Review.

10

P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.

Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G. Ketabi-Kiyanvash N, et al. Addict Biol. 2003 Dec;8(4):413-8. doi: 10.1080/13556210310001646475. Addict Biol. 2003. PMID: 14690877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

123 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Search Results

123 results

Results by year